CMB Cambium Bio Limited
Healthcare · Biotechnology
· website
$0.41
52wk 0.34 – 0.60
Overall
—
Value
—
Growth
—
Health
—
Quality
—
Momentum
—
Dividend
—
Price
About Cambium Bio Limited
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.
Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$12.07M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
-0.14
Dividend yield
—
Payout ratio
0.0%
Beta
-0.13
EV / EBITDA
-2.42
Price / Book
3.63
ROE
-167.6%
Operating margin
-264.5%
Net margin
0.0%
Total cash
$774,313
Total debt
$413,564
Current ratio
1.15
Debt / Equity
0.16
Free cash flow
$-3.46M
Avg volume
2,829
Latest annual results
(FY ending 30 Jun 2025)
- Revenue—
- Gross profit—
- Operating income-$4.76M
- Net income-$3.84M
- Diluted EPS-0.21
- Free cash flow-$5.25M
- Net debt$316.30K